tiprankstipranks
Trending News
More News >
Agilent (A)
NYSE:A
US Market
Advertisement

Agilent (A) Stock Forecast & Price Target

Compare
3,140 Followers
See the Price Targets and Ratings of:

A Analyst Ratings

Moderate Buy
12Ratings
Moderate Buy
7 Buy
5 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Agilent
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

A Stock 12 Month Forecast

Average Price Target

$143.82
▲(3.69% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Agilent in the last 3 months. The average price target is $143.82 with a high forecast of $165.00 and a low forecast of $125.00. The average price target represents a 3.69% change from the last price of $138.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"105":"$105","166":"$166","120.25":"$120.3","135.5":"$135.5","150.75":"$150.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$165.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143.82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$143.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$125.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[105,120.25,135.5,150.75,166],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,138.58,140.6123076923077,142.6446153846154,144.6769230769231,146.70923076923077,148.74153846153848,150.77384615384616,152.80615384615385,154.83846153846156,156.87076923076924,158.90307692307692,160.93538461538463,162.96769230769232,{"y":165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,138.58,138.98307692307694,139.38615384615386,139.78923076923078,140.1923076923077,140.59538461538463,140.99846153846156,141.40153846153845,141.80461538461537,142.2076923076923,142.61076923076922,143.01384615384615,143.41692307692307,{"y":143.82,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,138.58,137.53538461538463,136.49076923076925,135.44615384615386,134.40153846153848,133.3569230769231,132.3123076923077,131.2676923076923,130.22307692307692,129.17846153846153,128.13384615384615,127.08923076923077,126.04461538461538,{"y":125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":145.38,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":135.77,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.46,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":150.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.12,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.02,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.27,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":124.96,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.58,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$165.00Average Price Target$143.82Lowest Price Target$125.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$130
Hold
-6.27%
Downside
Reiterated
10/03/25
We expect a nice pricing benefit, with early checks showing +20% on like-for-like columns and success similar to WAT's MaxPeak column launch a few years ago could add an LSD% to LCMS consumables business (+25-50 bps to LDG). Highlighting Agilent's first major column launch in a decade. Earlier this week, Agilent introduced Altura Ultra Inert HPLC columns, which serve biopharma applications including peptides, GLP-1s and oligos. Key performance attributes include up to 2x sensitivity and 3x signal-to-noise vs. competitors, and up to 30x higher peak area with the 1290 Infinity III LC system. The columns have been in development for several years and represent the first major launch for Agilent's column business in a decade (did have application-specific releases in recent years). Pricing color.
TR | OpenAI - 4o Analyst forecast on A
TR | OpenAI - 4o
TR | OpenAI - 4o
$147
Buy
5.98%
Upside
Reiterated
10/02/25
AI Generated ArticleAI Generated Article
Barclays Analyst forecast on A
Barclays
Barclays
$125$150
Hold
8.15%
Upside
Reiterated
10/02/25
Agilent price target raised to $145 from $125 at BarclaysAgilent price target raised to $145 from $125 at Barclays
Bank of America Securities Analyst forecast on A
Bank of America Securities
Bank of America Securities
$130
Hold
-6.27%
Downside
Reiterated
09/25/25
Agilent's Balanced Outlook: Hold Rating Amid Growth Prospects and Valuation Concerns
Wells Fargo
$140$150
Buy
8.15%
Upside
Reiterated
09/15/25
Wells Fargo Reaffirms Their Buy Rating on Agilent (A)
TD Cowen
$150
Buy
8.15%
Upside
Reiterated
09/05/25
TD Cowen Keeps Their Buy Rating on Agilent (A)
Leerink Partners Analyst forecast on A
Leerink Partners
Leerink Partners
$135$140
Buy
0.94%
Upside
Reiterated
09/01/25
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and Edwards Lifesciences (NYSE: EW)
Robert W. Baird
$141$142
Buy
2.38%
Upside
Reiterated
08/28/25
Agilent price target raised to $142 from $141 at BairdAgilent price target raised to $142 from $141 at Baird
Citi
$165
Buy
18.96%
Upside
Reiterated
08/28/25
Citi Reaffirms Their Buy Rating on Agilent (A)
KeyBanc
Hold
Reiterated
08/28/25
KeyBanc Remains a Hold on Agilent (A)
Bernstein Analyst forecast on A
Bernstein
Bernstein
$125
Hold
-9.88%
Downside
Reiterated
08/28/25
Agilent's Strong Revenue Growth Offset by Margin Concerns: Hold Rating Maintained
J.P. Morgan Analyst forecast on A
J.P. Morgan
J.P. Morgan
$155
Buy
11.75%
Upside
Reiterated
08/28/25
J.P. Morgan Reaffirms Their Buy Rating on Agilent (A)
Evercore ISI Analyst forecast on A
Evercore ISI
Evercore ISI
$130$128
Hold
-7.71%
Downside
Reiterated
08/28/25
Evercore ISI Keeps Their Hold Rating on Agilent (A)
UBS
$150$130
Hold
-6.27%
Downside
Reiterated
05/29/25
Agilent (A) Gets a Hold from UBS
Stifel Nicolaus Analyst forecast on A
Stifel Nicolaus
Stifel Nicolaus
$151
Buy
8.87%
Upside
Reiterated
05/29/25
Agilent's Strong Performance and Promising Outlook: A Buy Recommendation by Daniel Arias
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies
$130
Hold
-6.27%
Downside
Reiterated
10/03/25
We expect a nice pricing benefit, with early checks showing +20% on like-for-like columns and success similar to WAT's MaxPeak column launch a few years ago could add an LSD% to LCMS consumables business (+25-50 bps to LDG). Highlighting Agilent's first major column launch in a decade. Earlier this week, Agilent introduced Altura Ultra Inert HPLC columns, which serve biopharma applications including peptides, GLP-1s and oligos. Key performance attributes include up to 2x sensitivity and 3x signal-to-noise vs. competitors, and up to 30x higher peak area with the 1290 Infinity III LC system. The columns have been in development for several years and represent the first major launch for Agilent's column business in a decade (did have application-specific releases in recent years). Pricing color.
TR | OpenAI - 4o Analyst forecast on A
TR | OpenAI - 4o
TR | OpenAI - 4o
$147
Buy
5.98%
Upside
Reiterated
10/02/25
AI Generated ArticleAI Generated Article
Barclays Analyst forecast on A
Barclays
Barclays
$125$150
Hold
8.15%
Upside
Reiterated
10/02/25
Agilent price target raised to $145 from $125 at BarclaysAgilent price target raised to $145 from $125 at Barclays
Bank of America Securities Analyst forecast on A
Bank of America Securities
Bank of America Securities
$130
Hold
-6.27%
Downside
Reiterated
09/25/25
Agilent's Balanced Outlook: Hold Rating Amid Growth Prospects and Valuation Concerns
Wells Fargo
$140$150
Buy
8.15%
Upside
Reiterated
09/15/25
Wells Fargo Reaffirms Their Buy Rating on Agilent (A)
TD Cowen
$150
Buy
8.15%
Upside
Reiterated
09/05/25
TD Cowen Keeps Their Buy Rating on Agilent (A)
Leerink Partners Analyst forecast on A
Leerink Partners
Leerink Partners
$135$140
Buy
0.94%
Upside
Reiterated
09/01/25
Analysts Offer Insights on Healthcare Companies: Agilent (NYSE: A) and Edwards Lifesciences (NYSE: EW)
Robert W. Baird
$141$142
Buy
2.38%
Upside
Reiterated
08/28/25
Agilent price target raised to $142 from $141 at BairdAgilent price target raised to $142 from $141 at Baird
Citi
$165
Buy
18.96%
Upside
Reiterated
08/28/25
Citi Reaffirms Their Buy Rating on Agilent (A)
KeyBanc
Hold
Reiterated
08/28/25
KeyBanc Remains a Hold on Agilent (A)
Bernstein Analyst forecast on A
Bernstein
Bernstein
$125
Hold
-9.88%
Downside
Reiterated
08/28/25
Agilent's Strong Revenue Growth Offset by Margin Concerns: Hold Rating Maintained
J.P. Morgan Analyst forecast on A
J.P. Morgan
J.P. Morgan
$155
Buy
11.75%
Upside
Reiterated
08/28/25
J.P. Morgan Reaffirms Their Buy Rating on Agilent (A)
Evercore ISI Analyst forecast on A
Evercore ISI
Evercore ISI
$130$128
Hold
-7.71%
Downside
Reiterated
08/28/25
Evercore ISI Keeps Their Hold Rating on Agilent (A)
UBS
$150$130
Hold
-6.27%
Downside
Reiterated
05/29/25
Agilent (A) Gets a Hold from UBS
Stifel Nicolaus Analyst forecast on A
Stifel Nicolaus
Stifel Nicolaus
$151
Buy
8.87%
Upside
Reiterated
05/29/25
Agilent's Strong Performance and Promising Outlook: A Buy Recommendation by Daniel Arias
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Agilent

1 Month
xxx
Success Rate
27/39 ratings generated profit
69%
Average Return
+2.11%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 69.23% of your transactions generating a profit, with an average return of +2.11% per trade.
3 Months
xxx
Success Rate
27/41 ratings generated profit
66%
Average Return
+3.08%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 65.85% of your transactions generating a profit, with an average return of +3.08% per trade.
1 Year
Success Rate
30/39 ratings generated profit
77%
Average Return
+16.93%
reiterated a buy rating 19 days ago
Copying Brandon Couillard's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +16.93% per trade.
2 Years
xxx
Success Rate
27/39 ratings generated profit
69%
Average Return
+23.42%
reiterated a xxx
rating 19 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +23.42% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
1
0
0
0
0
Buy
19
26
27
26
17
Hold
16
13
10
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
39
37
35
25
In the current month, A has received 17 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. A average Analyst price target in the past 3 months is 143.82.
Each month's total comprises the sum of three months' worth of ratings.

A Financial Forecast

A Earnings Forecast

Next quarter’s earnings estimate for A is $1.58 with a range of $1.58 to $1.60. The previous quarter’s EPS was $1.37. A beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year A has Preformed in-line its overall industry.
Next quarter’s earnings estimate for A is $1.58 with a range of $1.58 to $1.60. The previous quarter’s EPS was $1.37. A beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year A has Preformed in-line its overall industry.

A Sales Forecast

Next quarter’s sales forecast for A is $1.83B with a range of $1.82B to $1.84B. The previous quarter’s sales results were $1.74B. A beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year A has Preformed in-line its overall industry.
Next quarter’s sales forecast for A is $1.83B with a range of $1.82B to $1.84B. The previous quarter’s sales results were $1.74B. A beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year A has Preformed in-line its overall industry.

A Stock Forecast FAQ

What is A’s average 12-month price target, according to analysts?
Based on analyst ratings, Agilent’s 12-month average price target is 143.82.
    What is A’s upside potential, based on the analysts’ average price target?
    Agilent has 3.69% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is A a Buy, Sell or Hold?
          Agilent has a consensus rating of Moderate Buy which is based on 7 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Agilent’s price target?
            The average price target for Agilent is 143.82. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $165.00 ,the lowest forecast is $125.00. The average price target represents 3.69% Increase from the current price of $138.7.
              What do analysts say about Agilent?
              Agilent’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of A?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis